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Abstract: Zinc (Zn) deficiency is a common aliment predicted to affect 17% of the world’s population.
Zinc is a vital micronutrient used for over 300 enzymatic reactions and multiple biochemical and
structural processes in the body. Although whole blood, plasma, and urine zinc decrease in severe zinc
deficiency, accurate assessment of zinc status, especially in mild to moderate deficiency, is difficult
as studies with these biomarkers are often contradictory and inconsistent. Hence, as suggested
by the World Health Organization, sensitive and specific biological markers of zinc status are still
needed. In this review, we provide evidence to demonstrate that the LA:DGLA ratio (linoleic
acid:dihomo-γ-linolenic acid ratio) may be a useful additional indicator for assessing Zn status more
precisely. However, this biomarker needs to be tested further in order to determine its full potential.
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1. Introduction
Zinc (Zn) deficiency was first described in humans in the early 1960s, in Middle Eastern, male
adolescent dwarfs consuming plant-based diets [1]. Subsequently, Zn deficiency has been identified in
many other regions of the world, and it became evident that dietary deficiency of Zn in humans is
a widespread phenomenon. Today, Zn deficiency affects around 17% of the world’s population [2].
During the last 50 years, tremendous advances have been made both in our basic and clinical
understanding of Zn metabolism [3]. Major progress has been made in understanding the importance
of Zn as a structural and catalytic factor in a wide range of biological reactions, in uncovering
the cellular Zn absorption and excretion mechanisms, and in clarifying the activities of major Zn
transporters (15 Zip and 10 ZnT transporters) [4,5]. A significant research effort has tried to identify a
physiological biomarker that predicts Zn status truthfully, especially in mild to moderate Zn deficiency.
However, to this day, we are still without an entirely accurate biomarker of Zn status. In 2009, Lowe
and colleagues evaluated 32 biomarkers in their review and identified only three as potentially useful:
serum/plasma Zn concentrations, hair Zn concentration, and urinary Zn excretion [6]. Similarly, the
BOND (Biomarkers of Nutrition for Development) Zinc Expert Panel recommended the following
zinc biomarkers for use: dietary intakes, plasma/serum Zn concentrations, and stunting [7]. Last year,
an update on Zn biomarkers was provided, recognizing a few as emerging biomarkers that require
further investigation: Zn-dependent proteins, taste acuity, oxidative stress, and DNA integrity [8].
This review is a summary of research related to the LA:DGLA ratio (linoleic
acid:dihomo-γ-linolenic acid ratio) as a novel biomarker of Zn status. We describe the chemical
structure and function of the ∆6 desaturase enzyme, outline the current knowledge related to the role
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of Zn in desaturase activity and fatty acid metabolism, and provide recent data that demonstrates the
usefulness of the LA:DGLA ratio to be used as a potentially new biomarker of Zn status. Lastly, we
allude to further research needed on this topic.
2. The Limitations of the Currently Used Biomarkers: “Emerging” Biomarkers
All of the currently accepted and commonly used biomarkers of Zn status have certain
limitations. Serum/plasma Zn, hair Zn concentration, and urinary Zn levels tend to fall in severe
Zn depletion [9]. However, while plasma Zn concentration responds to altered intake over a short
period of time, low plasma Zn concentrations do not remain constant for an extended period due to
the homeostatic mechanisms that act to maintain plasma zinc concentration within the physiologic
range; by maintaining losses via the GI (gastrointestinal) tract and kidneys [6]. Similarly, dietary
Zn intake very often is not correlated with plasma zinc status, and does not realistically reflect the
nutritional state of an individual [7,10–12]. For example, unchanged plasma/serum Zn concentrations
were observed with intakes as low as 2.8 mg kg−1 to as high as 40 mg kg−1, showing the limitation of
plasma Zn status to reliably present the dietary Zn intake [13,14]. Serum Zn levels tend to rise and
then fall after a meal [15].
While urinary Zn decreases under severe Zn deficiency [16], the precise evaluation of Zn status
in mild to moderate Zn deficiency is challenging, as studies with this biomarker give inconsistent
and conflicting results [6]. Urinary Zn has been shown to be a poor indicator of early stage Zn
deficiency [14,16].
Recently, a few studies provided some evidence to support the effectiveness of hair Zn
concentrations in predicting the Zn status of individuals [17–19]. The hair Zn biomarker has some
advantages, such as low cost and viability; however, hair zinc still lacks sufficient evidence towards
validity as a method to assess Zn status [8,20]. Finally, the reliability of all currently used biomarkers
under infection and inflammatory conditions is intricate [6,7]. Plasma Zn concentration can fall as a
result of factors not related to Zn status or dietary Zn intake, i.e., infections, inflammation, trauma,
and stress [7].
An indicator that truthfully represents Zn status under various physiological conditions in humans
is still missing [7]. The role of Zn in various processes and pathways in the body is multifaceted, and
this may indicate that one single biomarker may never be sufficiently sensitive and that we need to use
a spectrum of Zn biomarkers to be able to precisely differentiate between various Zn deficiency states.
Emerging biomarkers are defined as ‘biomarkers for which there is some theoretical basis of a
relationship to zinc intake or status, but the testing is insufficient to confirm the relation’ [8]. Currently,
nail Zn concentration, Zn-dependent proteins, oxidative stress, DNA integrity, and taste acuity are
placed in the group of emerging biomarkers [8]. However, for many of the newly identified biomarkers,
insufficient evidence is available to demonstrate their true potential and further studies are needed to
confirm which ones can be used as biomarkers of Zn status. In this review, we provide the existing
evidence to show that the LA:DGLA ratio is likewise an emerging biomarker of Zn status that needs to
be assessed further.
3. Delta 6 Desaturase: Structure, Regulation, and Function
Delta 6 desaturase (∆6 desaturase, D6D or ∆-6-desaturase) is a membrane-bound desaturase
enzyme required for the synthesis of polyunsaturated fatty acids (PUFA). The enzyme is molecularly
identical across all living organisms. ∆6 desaturase is widely expressed in human tissues, in the
liver, the membrane of red blood cells, lung, and heart, with the highest levels being present in the
brain [21,22].
Linoleic acid (LA) is an essential omega 6 (n = 6) fatty acid that cannot be synthetized in the
human body and must be obtained from the diet to ensure the appropriate development of various
cells throughout the body [23]. It is the most abundant PUFA in human tissues [24]. LA is a metabolic
precursor of dihomo-γ-linolenic acid (DGLA) (Figure 1). ∆6 desaturases are rate-limiting enzymes
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in the synthesis of PUFA, responsible for conversion of LA to DGLA, and the enzyme catalyzes the
addition of a double bond at the sixth carbon-carbon bond position from the carboxylic acid end in
fatty acids [22,25].
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elongase to dihomo-γ-linolenic acid (DGLA, 20:3-6). Modified from: Meesapyodsuk & Qiu, 2012 [25]. 
The first ∆6 desaturase gene was cloned in 1993 from a cyanobacterium, Synechocystis [26]. 
Subsequently, desaturases have been identified and characterized from a wide range of species, and 
in 1997 the first eukaryotic ∆6 desaturase gene was cloned [27,28]. Mammalian ∆6 desaturase encoded 
gene is a protein made of a cytochrome b5-like domain, attached to the N-terminus of the main 
desaturation domain, and a histidine motif, located on a desaturation domain at the C-terminus [29]. 
The histidine sequence is made of three highly conserved histidine-rich motifs, i.e., HX3-4H, HX2-
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Figure 2. Schematic presentation of the structure of a ∆6 desaturase enzyme. A cytochrome b5-like 
domain is attached to the N-terminus and a histidine motif is located at the C-terminus. The histidine 
sequence is made of three histidine-rich motifs. The first histidine of the third motif is often replaced 
by glutamine. NADPH reductase has a Zn-dependent activity. NADH: nicotinamide adenine 
dinucleotide hydride; NADPH: nicotinamide adenine dinucleotide phosphate-oxidase. 
To date, there has been limited information available on how the expression of the ∆6 desaturase 
is regulated. Some scientists believe that the regulation is achieved by the feedback control of the 
transcriptional regulation of fatty acid desaturase genes, mediated through signaling pathways 
activated by sensors embedded in cellular membranes, in response to environmental factors [32]. 
There is also some evidence showing that ∆6 desaturase enzymatic activity may be determined by 
tissue-specific mechanisms that involve both pre- and post-translational events [25]. 
NADPH reductase is important in the action of the ∆6 desaturase and is a Zn-dependent enzyme 
[33–35]. Typically, the Zn atom is bound to three or four ligands, which are composed of amino acids 
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The first ∆6 desaturase gene was cloned in 1993 from a cyanobacterium, Synechocystis [26].
Subsequently, desaturases have been identified and characterized from a wide range of species,
and in 1997 the first eukaryotic ∆6 desaturase gene was cloned [27,28]. Mammalian ∆6 desaturase
encoded gene is a protein made of a cytochrome b5-like domain, attached to the N-terminus of
the main desaturation domain, and a histidine motif, located on a desaturation domain at the
C-terminus [29]. The histidine sequence is made of three highly conserved histidine-rich motifs,
i.e., HX3-4H, HX2-3HH, and H/QX2-3HH (Figure 2). The first histidine of the third motif is commonly
substituted by glutamine [27]. The conversion of glutamine back to histidine results in the loss of
activity, suggesting that the process might be very important not only for the structural configuration
of desaturases, but also for their activity [30]. The gene coding for ∆6 production is located on human
chromosome 11 (11q12.2-13.1), and is made of 12 exons and 11 introns [31].
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Figure 2. Schematic presentation of the structure of a ∆6 desaturase enzyme. A cytochrome b5-like
domain is attached to the N-terminus and a histidine motif is located at the C-terminus. The histidine
sequence is made of three histidine-rich motifs. The first histidine of the third motif is often replaced by
glutamine. NADPH reductase has a Zn-dependent activity. NADH: nicotinamide adenine dinucleotide
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is regulated. Some scientists believe that the regulation is achieved by the feedback control of the
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NADPH reductase is important in the action of the ∆6 desaturase and is a Zn-dependent
enzyme [33–35]. Typically, the Zn atom is bound to three or four ligands, which are composed
of amino acids residues with histidine being the most frequent, followed by glutamic acid, aspartic
acid, and cysteine [36]. Finally, the mutation of the cytochrome b5 domain is critical for the activity of
∆6 desaturases [37,38].
4. The Role of Zn in the Regulation of ∆6 Desaturase Activity and Fatty Acid Metabolism
Zn is an essential component of many enzymes and constitutes a part of their prostetic group [39].
It is present in DNA and RNA polymerases, dehydrogenases, and desaturases, regulating their
functions via its catalytic, structural, or regulatory role. Over the years it has been noted that Zn is
an important co-factor for the metabolism of fatty acids [40]. Zn is also necessary for at least two
stages in essential fatty acid (EFA) metabolism; the conversion of linoleic acid to γ-linolenic acid,
and the mobilization of dihomo-γ-linolenic acid (DGLA) to arachidonic acid [41]. Zinc has an effect
on ∆6 desaturase itself [41], and affects linoleic acid absorption [42]. Once it was identified that Zn
and essential fatty acid deficiencies give similar symptoms, a close association between fatty acid
metabolism and Zn status was proposed [41,43,44].
Over the years, a number of studies have demonstrated an effect of Zn deficiency on the
metabolism of essential fatty acids by impaired ∆6 desaturation activity [34,42,44–46]. On the other
hand, there are a few studies completed in early 1990 that showed no role of Zn in fatty acid
desaturation [47–51].
The effect of Zn deficiency on ∆5 and ∆6 activity was initially investigated by a number of
groups in the early 1980s [42,45,52]. The findings were consistent, proving the reduced activity of ∆6
desaturase during Zn deficiency. Ayala and Branner [42] used male weaning Wistar rats and examined
the influence of Zn on desaturating enzymes of liver and testes microsomes and their impact on fatty
acid and lipid alterations of the tissues. The rats were fed Zn-adequate (55 ppm of Zn) or Zn-deficient
diets (1.2 ppm of Zn) for 60 days. The progress of the effect of Zn deficiency was notable; Zn deficiency
induced a decrease of essential fatty acids of the linoleic family in plasma after only 18 days, which
indicates that Zn deficiency causes a rapid change in desaturase activity [42]. The activities of both
desaturases were affected by Zn deficiency, but to a different degree. The same level of Zn deficiency
caused a 45% reduction in ∆6 activity, while ∆5 was almost completely attenuated [42].
Similar findings were provided by Cunnane and Wahle [53] when it was shown that Zn modulates
linoleic acid metabolism in rat mammary glands, modifying the ∆6 desaturation of microsomes.
Specifically, 38 Sprague-Dawley rats were fed either a purified Zn-supplemented or a Zn-deficient
diet for six weeks. The effects of Zn deficiency on the fatty acid composition of plasma lipids and
microsomes of liver, intestine, and testes were studied. Among the polyunsaturated fatty acids, DGLA
was significantly reduced by the Zn-deficient diet. Interestingly, the activity of ∆6 activity in liver
microsomes was decreased by 25%, while the ∆5 desaturation was reduced by 53% in Zn-depleted
rats. In addition, hypertriglyceridemia was observed in the serum of Zn-deficient rats. This study
demonstrated that Zn supplementation returned serum triglycerides to normal levels, which shows
a strong physiological interaction between Zn and EFAs (essential fatty acids) and confirms that Zn
deficiency is responsible for the defects in desaturation [54].
Ten years later, studies completed by Eder and Kirchgessner [44,55,56] provided somewhat
contradictory results, demonstrating that Zn deficiency does not affect ∆5 and ∆6 desaturation.
The experiments were conducted using various types of dietary fats, including coconut, sunflower,
or linseed oil. The proposition was that the activities of ∆5 and ∆6 desaturase depend on the type
of dietary fat consumed. Diets rich in fats with high levels of polyunsaturated fatty acids suppress
activities of desaturases, while fat free diets significantly raise the activities of these desaturases.
Later in 1995, the authors suggested that one reason for the contradiction between the findings
might be the experimental design used in the studies, where the effects of Zn deficiency on desaturase
activity was misperceived by a low food intake. After that, the role of Zn in desaturase activity was
Nutrients 2017, 9, 825 5 of 11
examined by a serious of experiments with Zn-deficient rats using a force-feeding technique that
ensures identical food intake [44]. ∆5 and ∆6 desaturation was investigated in the presence of Zn
deficiency in force-fed rats by previously raising the levels of enzymes by feeding a fat-free diet [44].
Zn-deficient rats fed a diet consisting of 5% safflower oil had lower levels of total PUFA than the
corresponding rats fed a Zn-adequate diet. The authors clearly demonstrated the role of Zn in ∆5
and ∆6 desaturation in subjects with adequate food and energy intake. Similarly, in subjects with a
low-fat intake (fat-free diets), the effect of Zn deficiency on ∆6 desaturation activity was even more
pronounced, with a significantly lower activity of the enzyme being observed [44].
In 1999, Waldhauser and colleagues [57] looked at the ratio between n-3 PUFA and n-6 PUFA in
zinc-deficient animals. Four groups of rats were fed zinc-deficient (0.5 mg Zn kg−1) or zinc-adequate
(45 mg Zn kg−1) diets with either olive oil or linseed oil as the source of fat. To ensure an adequate
food intake, the rats were force-fed by gastric tube over a period of 13 days. The study confirmed
that Zn deficiency influences the metabolic balance between n-3 and n-6 PUFA, whereas saturated
and MUFA (monounsaturated fatty acids) seem to remain unaffected by Zn deficiency. In the rats
that were fed linseed oil, zinc deficiency caused a marked increase in the ratio between n-3 and n-6
polyunsaturated fatty acids in liver phospholipids, particularly in phosphatidylcholine. In contrast, in
the rats that were fed olive oil, Zn deficiency had only slight effects on the fatty acid composition of
the liver phospholipids. Therefore, this study confirms the previous results demonstrating that the
effects of Zn deficiency on lipid metabolism may be influenced by the type of dietary fat. However, it
must be noted that only hepatic ∆6 desaturase enzymatic activity may be reliant upon the composition
of dietary fat [58]. This is not applicable to all other tissues. While, the consumption of an essential
fatty acid-deficient diet is paralleled by a similar increase in the hepatic abundance of ∆6 desaturase
mRNA and the increase in hepatic ∆6 desaturase activity [21], ∆6 desaturase activity was very low in
non-hepatic tissues [58,59].
It seems that the potential role of dietary fat on desaturase activity, under relevant conditions, is
only related to hepatic tissue. Similarly, in situations when EFA deficiency is of dietary origin, there is
an increased attempt to synthetize more linoleic acid, so ∆6 desaturase activity is increased. However,
when EFA deficiency is metabolic (as in Zn deficiency) ∆6 activity is inhibited [60]. Finally, increased
∆6 desaturase activity will not necessarily lead to the elevated metabolizing of linoleic acid and its
conversion to DGLA. Below, we summarize the findings that confirm the interaction between Zn
deficiency and the metabolism of linoleic acid via desaturase enzymes:
1. Zn may have a role in the absorption of linoleic acid. Lower levels of Zn produce lower levels of
linoleic acid [60].
2. Zn has a role in relation to the NADH-NADPH cycle (Figure 2) [35].
3. Cytochrome P-450 activity is significantly reduced under Zn deficiency [34].
4. Zn deficiency reduces the availability of linoleic acid metabolites γ-linolenic and arachidonic
acid [52,61].
5. Zn deficiency decreases the mobilization of DGLA from tissue stores [62].
6. Zn is needed in the formation of GLA and in the mobilization of DGLA [41].
7. EFA supplementation worsens the effect of Zn deficiency [43,52,63].
8. Zn deficiency decreases the esterification of essential fatty acids into phospholipids [46].
9. During Zn deficiency, linoleic acid accumulates in tissues when EFA supplements are
administered [63].
10. Zn deficiency results in a higher concentration of linoleic and a lower concentration of arachidonic
acid in tissue phospholipids [34].
11. Zn-deficient subjects have an increased β-oxidation of linoleic acid, resulting in decreased
amounts of linoleic acid available to be metabolized into arachidonic acid [64].
12. The most important EFA functions are carried out by molecules downstream of GLA [41].
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13. In animals exposed to diets deficient in essential fatty acids, the characteristic symptoms develop
much more rapidly if the diets are also deficient in Zn [43,65].
14. The inhibition of the desaturases by Zn deficiency is so strong that it causes a more rapid decline
in tissue arachidonic acid and docosahexaenoic acid than does the direct dietary deficiency of all
the omega 6 or omega 3 polyunsaturated fatty acids [64].
15. Enzymes involved in prostaglandin synthesis are also Zn-dependent, and defects in prostaglandin
synthesis are observed under Zn deficiency [52].
In summary, Zn has both a direct role in the modulation of desaturase activities involved in the
fatty acid metabolism and an indirect effect on fatty acids by influencing their absorption, oxidation,
and incorporation [34]. Zn deficiency causes inconsistencies in the ratio of desaturase substrates and
products, and linoleic acid (LA) and dihomo-γ-linolenic acid (DGLA), respectively (Figure 1). The most
important EFA functions are carried out by molecules downstream of GLA. The ∆6-catalyzed step
required for the transformation of LA to DGLA is generally the highest flux pathway, so an elevation
in the LA:DGLA ratio could be a sensitive marker for Zn deficiency.
5. The LA:DGLA Ratio as a Biomarker of Zn Status, Current Evidence
In 2014, the concept of the essential role of Zn for ∆6 desaturase activity was reinvented. For the
first time, Reed et al. [66] tested and implemented a previously unexplored biomarker of zinc status
related to erythrocyte ∆6 desaturation, the LA:DGLA ratio. By using the chicken (Gallus gallus)
as a model, the authors evaluated the sensitivity of the erythrocyte LA:DGLA ratio to changes in
supplemental Zn intake. A significant negative correlation was found between dietary Zn deficiency
and the LA:DGLA ratio.
The Gallus gallus has a similar membrane fatty acid composition to mammals [67] and is highly
sensitive to dietary Zn manipulations [66,68–70], which makes it a potentially ideal animal model
for exploring changes in the production of essential fatty acids in relation to Zn nutrition. In the
original study, birds were fed either a Zn-adequate control diet (42.3 µg Zn g−1) or a Zn-deficient
diet (2.5 µg Zn g−1). Diets had identical FA (fatty acids) content/profile. The body weight, feed
consumption, Zn intake, and serum Zn concentrations of the birds were measured weekly, showing
higher values of all parameters in the Zn control versus the Zn-deficient diet group of birds (p < 0.05).
There was a relative increase in gene expression of the cytokines: tumor necrosis factor alpha (TNF-α),
interleukin 1 beta (IL-1β), and interleukin-6 (IL-6) in the control group. Other assessed parameters
included metal transporters (i.e., ZnT1, ZnT5, ZnT7, Zip6, Zip9); transcription factor: nuclear factor
kappa B (NF-κB); brush border enzymes: aminopeptidase, sucrose-isomaltase, Na+K+ATPase, sodium
glucose transport protein 1 (SGLT-1), and binding metallothionein-4 protein (MT4). These parameters
were found to not be significantly different between the groups. However, the expression of hepatic
∆6 desaturase was significantly higher in the control group (p < 0.001). Accordingly, the LA:DGLA
ratio was noticeably elevated in the low Zn compared to the control Zn group (22.6 ± 0.5% and
18.5 ± 0.5% w/w, respectively, p < 0.001). This study demonstrated that the erythrocyte LA:DGLA
is able to differentiate zinc status between zinc-adequate and zinc-deficient subjects. Furthermore,
variations in the LA:DGLA ratio were noticeable within seven days, signifying that this biomarker
can show changes in the dietary Zn status quickly and that it may be able to detect early stages of Zn
deficiency that usually, due to the lack of obvious signs and symptoms, pass unrecognized.
This proposed biomarker has been evaluated further in humans [71]. A study was completed on
healthy human volunteers, 25–55 years of age. The content of plasma phospholipid LA, DGLA, and
changes in the LA:DGLA ratio were compared to the dietary Zn intake and plasma Zn status in human
subjects. Participants were separated into two groups based on dietary Zn intakes, assessed using
three 24-h recall questionnaires provided on three non-consecutive days. There were no statistically
significant differences in the dietary intake of LA and PUFA among the groups of participants.
Plasma phospholipid fatty acid analysis was conducted by gas chromatography, and plasma analysis
of minerals was conducted by atomic absorption spectrometry.
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In addition, the study assessed correlations of plasma Zn and the LA:DGLA ratio with various
biochemical, anthropometrical, and hematological parameters. It was shown that while the plasma
Zn concentrations of participants remained unchanged (most likely due to the good homeostatic
regulation), there was a statistically significant difference in DGLA production and the LA:DGLA ratio
between the groups (p < 0.05). The concentration of plasma DGLA was decreased and the LA:DGLA
ratio was increased in people with lower dietary Zn intakes. Besides, docosatetraenoic acid (22:4n-6;
D5D) was also lower in the group of people with lower dietary Zn intake.
Finally, the efficacy of the LA:DGLA ratio to predict the Zn status of subjects consuming a
wheat-based diet, a diet more representative of a diet of the target Zn-deficient populations, was
recently evaluated in vivo by using the Gallus gallus model [72]. Two groups of birds (n = 15) were fed
two different diets, a “high-Zn” diet (46.5 ppm Zn) and a “low-Zn” diet (32.8 ppm Zn), for six weeks.
Dietary zinc intake, body weight, serum zinc, and the erythrocyte fatty acid profile were assessed.
Serum zinc concentrations were greater in the high-Zn group (p < 0.05). Similarly, the concentration
of Zn in tissues (feather and nail) was higher in the high-Zn group of birds as opposed to the birds
fed a low-Zn diet (p < 0.05). Duodenal mRNA expression of various Zn transporters (i.e., Zip4, Zip6,
Zip9, ZnT1, Znt5 and Znt7) demonstrated a higher mean value in the tissues collected from the birds
fed a low-Zn diet (n = 15, p < 0.05). The measurements of hepatic ∆6 desaturase expression showed
significant differences between the groups, with a higher mean value in birds fed high-Zn diets.
The LA:DGLA ratio was higher in the low-Zn group of birds at all time points measured (weeks 2, 4,
and 6). Once more, the LA:DGLA ratio responded to changes in dietary Zn intake. Even though both
groups of birds were fed Zn-deficient diets, with only 14 ppm differential in dietary Zn content, still
the LA:DGLA ratio differentiated clearly between the groups, which demonstrates the sensitivity of
the biomarker to change in accordance with dietary Zn intake.
6. Conclusions and Recommendations for Further Research
The evidence provided in this review demonstrate the potential of the LA:DGLA ratio to be used
as an additional biomarker of Zn status in humans. To date, research shows that the LA:DGLA ratio
corresponds to dietary Zn manipulations, both in animals and humans. This biomarker should be
tested and evaluated further to illuminate its full potential. This review provides some evidence to
justify the requirements for further research.
Well-controlled human dietary intervention trials are needed to examine the sensitivity of this
biomarker in larger healthy cohorts, as well as in Zn-deficient populations. Hence, additional research
is needed to elucidate any potential limitations of this biomarker, i.e., the effect of inflammatory
conditions and infection states on this biomarker. Similarly, the enzymatic activity of hepatic
desaturases should be compared to the expression and activity of ∆6 desaturases in non-hepatic
tissues in order to determine the exact role of dietary fats in ∆6 desaturase activity. Additional studies
are needed to clarify the potential impact of other nutrient deficiencies on the LA:DGLA ratio, in
particular the effect of iron and copper deficiencies. The effectiveness of the LA:DGLA ratio, in relation
to Zn status and Zn bioavailability over time, requires further investigation. The kinetics of other
desaturase enzymes in relation to Zn intake should also be tested (i.e., ∆5 desaturase). Finally, the
modifications of Zn-dependent proteins and genes at the main sites of Zn absorption, namely, in the
small intestine, in relation to Zn intake and the LA:DGLA ratio need to be tested and evaluated further.
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